Technology | January 19, 2011

GE to Distribute Interventional Oncology Navigation Systems

January 19, 2011 – GE Healthcare and Veran announced a strategic supplier agreement this week in which GE became the exclusive distributor and reseller of Veran’s ig4 fusion imaging angiography navigation system in the United States.

The deal brings together GE’s Innova angiography imaging systems and Veran’s electromagnetic navigation to create a comprehensive interventional oncology solution under a single point of contact. The system allows 4-D registration capability with for precise targeting of cancerous lesions.

The multimodality Veran ig4 system helps clinicians deliver instruments to small targets in difficult to access regions of the human body in order to diagnose and treat disease minimally invasively. The navigation system uses electromagnetic localization and 4-D (x, y, z time) registration to display an interventional instrument, such as a biopsy needle or ablation needle, on a computer monitor with respect to anatomic imaging and treatment planning.

This system is compatible with GE’s Innova imaging systems, which acquire CT-like patient images of the target organ(s) that can be exported to the navigation system in the same imaging suite, during the interventional procedure. The resulting displayed image provides navigation information to help physicians insert biopsy needles, ablation (radio frequency (RF), cryotherapy and microwave) probes and other devices through the skin more quickly and with greater target accuracy. Also, using Innova CT images with Veran ig4 system may help to reduce the absorbed radiation dose through decreased use of fluoroscopy.

“This is exciting news for our customers who want to perform complex procedures in a timely fashion with more confidence. The combined systems can help clinicians achieve greater accuracy, perform procedures more quickly and reduce radiation dose,” said Chantal Le Chat, general manager of interventional radiology, GE Healthcare.

”Partnering with a global company such as GE Healthcare to significantly increase the access of our cutting edge 4-D registration technology is a great step forward for Veran Medical,” said Jerome R. Edwards, president and CEO, Veran Medical Technologies. “GE Healthcare’s healthymagination vision is extremely synergistic with the mission that Veran Medical has by having its focus directed in the interventional oncology market.”

For more information: www.gehealthcare.com, www.veranmedical.com

Related Content

Merit Medical Announces Advanced Interventional Cardiology Transradial Intervention Education Course
News | Interventional Radiology | August 23, 2017
Merit Medical Systems Inc. will partner with internationally renowned interventional cardiologist Ferdinand Kiemeneij,...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Virtual Phantoms Inc. Releases VirtualDose-IR
Technology | Radiation Dose Management | August 07, 2017
Virtual Phantoms Inc. announced the release of VirtualDoseIR, a tool for assessing organ dose from interventional...
Moffitt Cancer Center Enhances Patient Care with Toshiba Medical's Infinix-i 4-D
News | Interventional Radiology | August 03, 2017
Cancer patients at Moffitt Cancer Center in Tampa, Fla., now have access to advanced diagnostic imaging for fast and...
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography | July 05, 2017
July 5, 2017 — Michigan Medicine recently became the first healthcare institution in the United States to install the
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
RaySafe Introduces Pro-Slit Camera for Accurate Focal Spot Measurement
Technology | Digital Radiography (DR) | June 27, 2017
Unfors RaySafe recently introduced the RaySafe Pro-Slit Phantom and the RaySafe Pro-Stand.
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Overlay Init